INCY vs. ZBH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at INCY and ZBH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | INCY | ZBH |
|---|---|---|
| Company Name | Incyte Corporation | Zimmer Biomet Holdings, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 16.83 billion USD | 20.94 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | November 4, 1993 | July 25, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of INCY and ZBH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | INCY | ZBH |
|---|---|---|
| 5-Day Price Return | 0.05% | 3.52% |
| 13-Week Price Return | 35.09% | 10.38% |
| 26-Week Price Return | 23.13% | 5.81% |
| 52-Week Price Return | 36.26% | -5.42% |
| Month-to-Date Return | 15.10% | 15.34% |
| Year-to-Date Return | 24.80% | 0.08% |
| 10-Day Avg. Volume | 1.86M | 1.86M |
| 3-Month Avg. Volume | 1.86M | 2.13M |
| 3-Month Volatility | 36.16% | 26.41% |
| Beta | 0.73 | 0.68 |
Profitability
Return on Equity (TTM)
INCY
24.09%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ZBH
6.62%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
ZBH’s Return on Equity of 6.62% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
INCY
18.99%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
ZBH
10.51%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
ZBH’s Net Profit Margin of 10.51% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
INCY
25.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ZBH
16.09%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
ZBH’s Operating Profit Margin of 16.09% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | INCY | ZBH |
|---|---|---|
| Return on Equity (TTM) | 24.09% | 6.62% |
| Return on Assets (TTM) | 15.81% | 3.74% |
| Net Profit Margin (TTM) | 18.99% | 10.51% |
| Operating Profit Margin (TTM) | 25.80% | 16.09% |
| Gross Profit Margin (TTM) | 93.41% | 71.06% |
Financial Strength
Current Ratio (MRQ)
INCY
2.85
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ZBH
1.87
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
ZBH’s Current Ratio of 1.87 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
INCY
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ZBH
0.60
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
ZBH’s Debt-to-Equity Ratio of 0.60 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
ZBH
5.76
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
ZBH’s Interest Coverage Ratio of 5.76 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | INCY | ZBH |
|---|---|---|
| Current Ratio (MRQ) | 2.85 | 1.87 |
| Quick Ratio (MRQ) | 2.55 | 0.80 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.60 |
| Interest Coverage Ratio (TTM) | 6.86 | 5.76 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ZBH
1.02%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Yield of 1.02% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ZBH
23.39%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Payout Ratio of 23.39% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | INCY | ZBH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.02% |
| Dividend Payout Ratio (TTM) | 0.00% | 23.39% |
Valuation
Price-to-Earnings Ratio (TTM)
INCY
19.33
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
INCY’s P/E Ratio of 19.33 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ZBH
22.82
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
In the lower quartile for the Health Care Equipment & Supplies industry, ZBH’s P/E Ratio of 22.82 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
INCY
3.67
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.67 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
ZBH
2.40
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
ZBH’s P/S Ratio of 2.40 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
INCY
3.16
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ZBH
1.44
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
ZBH’s P/B Ratio of 1.44 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | INCY | ZBH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.33 | 22.82 |
| Price-to-Sales Ratio (TTM) | 3.67 | 2.40 |
| Price-to-Book Ratio (MRQ) | 3.16 | 1.44 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.57 | 15.78 |